Effects of small molecular inhibitors on the binding between HIV-1 reverse transcriptase and DNA as revealed by SPR biosensor

Sensors and Actuators, B: Chemical

Volumn 122, Issue 1, 2007, Pages 243-252

  Wu, Lei ^a   Zhang, Qi ^b   Su, Li ^a   Huang, Minghui ^b   Zhao, Jianlong ^a   Yang, Mengsu ^a,b  

^a SHANGHAI INSTITUTE OF MICROSYSTEM AND INFORMATION TECHNOLOGY   (China)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

conformation change model; DNA templete primer duplex; HIV 1 RT; kinetics; NNRTIs and NRTIs; SPR biosensor

Indexed keywords

CONFORMATIONS; DNA; ENZYME INHIBITION; FATTY ACIDS; REACTION KINETICS; SURFACE PLASMON RESONANCE; VIRUSES;

MOLECULAR INHIBITORS; NERVONIC ACID (NA); NUCLEOSIDE-BASED REVERSE TRANSCRIPTASE INHIBITORS (NRTI); REVERSE TRANSCRIPTASE;

BIOSENSORS;

EID: 33847063852     PISSN: 09254005     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.snb.2006.05.025     Document Type: Article

References (67)

1. Ren J., Esnouf R.M., Hopkins A.L., Warren J., Balzarini J., Stuart D.I., and Stammers D.K. Crystal structures of HIV-1 reverse transcriptase in complex with carbocanilide derivatives. Biochemistry 37 (1998) 14394-14403
2. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54 (1999) 26-45
3. Maga G., Ubiali D., Salvetti R., Pregnolato M., and Spadari S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor Efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob. Agents Chemother. 44 (2000) 1186-1194
4. Kasai N., Mizushina Y., Sugawara F., and Sakaguchi K. Three-dimensional structural model analysis of the binding site of an inhibitor, nervonic acid, of both DNA polymerase beta and HIV-1 reverse transcriptase. J. Biochem. (Tokyo) 132 (2002) 819-828
5. Tronchet J.M., and Seman M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Curr. Top Med. Chem. 3 (2003) 1496-1511
6. Ono N.H., Fukushima K.M., Chermann J.C., and Barre-Sinoussi F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur. J. Biochem. 190 (1991) 469-476
7. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52 (2000) 673-751
8. Yang S.S., Cragg G.M., Newman D.J., and Bader J.P. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J. Nat. Prod. 64 (2001) 265-277
9. Tewtrakul S., Nakamura N., Hattori M., Fujiwara T., and Supavita T. Flavanone and flavonol glycosides from the leaves of Thevetia peruviana and their HIV-1 reverse transcriptase and HIV-1 integrase inhibitory activities. Chem. Pharm. Bull. 50 (2002) 630-635
10. Georgiadis M.M., Jessen S.M., Ogata C.M., Telesnitsky A., Goff S.P., and Hendrickson W.A. Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. Structure 3 (1995) 879-892
11. Shen L.L., Luo S.J.X.M., Cheng F., Xu Y.C., Chen K.X., Arnold E., Ding J.P., and Jiang H.L. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys. J. 84 (2003) 3547-3563
12. Rizzo R.C., Wang D.-P., Tirado-Rives J., and Jorgensen W.L. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles. J. Am. Chem. Soc. 122 (2000) 12898-12900
13. Peletskaya E.N., Kogon A.A., Tuske S., Arnold E., and Hughes S.H. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. J. Virol. 78 (2004) 3387-3397
14. Sluis-Cremer N., and Temiz N.A. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV Res. 2 (2004) 323-332
15. Jaju M., Beard W.A., and Wilson S.H. Human immunodeficiency virus type 1 reverse transcriptase. 3′-Azidodeoxythymidine 5′-triphosphate inhibition indicates two-step binding for template-primer. J. Biol. Chem. 270 (1995) 9740-9747
16. Villahermosa M.L., Martinez-Irujo J.J., Cabodevilla F., and Santiago E. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 36 (1997) 13223-13231
17. Canard B., Sarfati S.R., and Richardson C.C. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer. J. Biol. Chem. 273 (1998) 14596-14604
18. Canard B., Chowdhury K., Sarfati R., Doublie S., and Richardson C.C. The motif D loop of human immunodeficiency virus type 1 reverse transcriptase is critical for nucleoside 5′-triphosphate selectivity. J. Biol. Chem. 274 (1999) 35768-35776
19. Papadopulos-Eleopulos E., and Turner V.F. A critical analysis of the pharmacology of AZT. Curr. Med. Res. Opin. 15 Suppl 1 (1999) S1-S15
20. Isel C., Ehresmann C., Walter P., Ehresmann B., and Marquet R. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J. Biol. Chem. 276 (2001) 48725-48732
21. Scott W.A. The enzymatic basis for thymidine analogue resistance in HIV-1. AIDS Rev. 33 (2001) 194-200
22. Chamberlain P.P., Ren J., Nichols C.E., Douglas L., Lennerstrand J., Larder B.A., Stuart D.I., and Stammer D.K. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons, 41, 184, and 215. J. Virol. 76 (2002) 10015-10019
23. Ray A.S., Basavapathruni A., and Anderson K.S. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J. Biol. Chem. 277 (2002) 40479-40490
24. Sarafianos S.G., Clark Jr. A.D., Das K., Tuske S., Ilankumaran P., Ramesha A.R., Sayer J.M., Jerina D.M., Boyer P.L., Hughes S.H., and Arnold E. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21 (2002) 6614-6624
25. Hsiou Y., Ding J., Das K., Clark Jr. A.D., Hughes S.H., and Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7. A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4 (1996) 853-860
26. Jacobo-Molina A., Ding J., Nanni R.G., Clark Jr. A.D., Lu X., Tantillo C., Williams R.L., Kamer G., Ferris A.L., Clark P., Hizi A., Hughes S.H., and Arnold E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Ǻ resolution shows bent DNA. Proc. Natl Acad. Sci. USA 90 (1993) 6320-6324
27. Ding J., Das K., Hsiou Y., Sarafianos S.G., Clark Jr. A.D., Jacobo-Molina A., Tantillo C., Hughes S.H., and Arnold E. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J. Mol. Biol. 284 (1998) 1095-1111
28. Lavigne M., Polomack L., and Buc H. Structures of complexes formed by HIV-1 reverse transcriptase at a termination site of DNA synthesis. J. Biol. Chem. 276 (2001) 31439-31448
29. Sarafianos S.G., Das K., Tantillo C., Clark Jr. A.D., Ding J., Whitcomb J.M., Boyer P.L., Hughes S.H., and Arnold E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J. 20 (2001) 1449-1461
30. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
31. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., and Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2 (1995) 293-302
32. Divita G., Muller B., Immendorfer U., Gautel M., Rittinger K., Restle T., and Goody R.S. Kinetics of interaction of HIV reverse transcriptase with primer/template. Biochemistry 32 (1993) 7966-7971
33. Hsieh J.C., Zinnen S., and Modrich P. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 268 (1993) 24607-24613
34. Taylor P.B., Culp J.S., Debouck C., Johnson R.K., Patil A.D., Woolf D.J., Brooks I., and Hertzberg R.P. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J. Biol. Chem. 269 (1994) 6325-6331
35. Divita G., Rittinger K., Geourjon C., Deleage G., and Goody R.S. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J. Mol. Biol. 245 (1995) 508-521
36. Schuck P. Kinetics of ligand binding to receptor immobilized in a polymer matrix, as detected with an evanescent wave biosensor. 1. A computer simulation of the influence of mass transport. Biophys. J. 70 (1996) 1230-1249
37. Wohrl B.M., Krebs R., Goody R.S., and Restle T. Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate. J. Mol. Biol. 292 (1999) 333-344
38. Zang H., Harris T.M., and Guengerich F.P. Kinetics of nucleotide incorporation opposite DNA bulky guanine N2 adducts by processive bacteriophage T7 DNA polymerase (exonuclease-) and HIV-1 reverse transcriptase. J. Biol. Chem. 280 (2005) 1165-1178
39. Tsoi P.Y., Yang J., Sun Y.-t., Sui S.-f., and Yang M. Surface plasmon resonance study of DNA polymerases binding to template/primer DNA duplexes immobilized on supported lipid monolayers. Langmuir 16 (2000) 6590-6596
40. Gorshkova I., Rausch J.W., Le Grice S.F., and Crouch R.J. HIV-1 reverse transcriptase interaction with model RNA-DNA duplexes. Anal. Biochem. 291 (2001) 198-206
41. Tsoi P.Y., and Yang M.S. Kinetic study of various binding modes between human DNA polymerase β and different DNA substrates by surface-plasmon-resonance biosensor. Biochem. J. 361 (2002) 317-325
42. Linnell J., Mott R., Field S., Kwiatkowski D.P., Ragoussis J., and Udalova I.A. Quantitative high-throughput analysis of transcription factor binding specificities. Nucl. Acids Res. 32 (2004) e44
43. Rittinger K., Divita G., and Goody R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 92 (1995) 8046-8049
44. http://www.biacore.com
45. Spence R.A., Anderson K.W.K.S., and Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267 (1995) 988-993
46. Motakis D., and Parniak M.A. Tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46 (2002) 1851-1856
47. Karlsson R., and Falt A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J. Immunol. Methods 200 (1997) 121-133
48. Ciolkowski M.L., Fang M.M., and Lund M.E. A surface plasmon resonance method for detecting multiple modes of DNA-ligand interactions. J. Pharm. Biomed. Anal. 22 (2000) 1037-1045
49. Luo J., Zhou J., and Zou W. Antibody-antigen interactions measured by surface plasmon resonance: global fitting of numerical integration algorithms. J. Biochem. (Tokyo) 130 (2001) 553-559
50. Bergethon P.R. The Foundations of Molecular Biophysics (1998), Springer-Verlag, New York pp. 445-448
51. Glaser R.W. Antigen-antibody binding and mass transport by convection and diffusion to a surface: a two-dimensional computer model of binding and dissociation kinetics. Anal. Biochem. 213 (1993) 152-161
52. Christensen L.L. Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal. Biochem. 249 (1997) 153-164
53. Richalet-Secordel P.M., Rauffer-Bruyere N., Christensen L.L., Ofenloch-Haehnle B., Seidel C., and Van Regenmortel M.H. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal. Biochem. 249 (1997) 165-173
54. Wohrl B.M., Georgiadis M.M., Telesnitsky A., Hendrickson W.A., and Le Grice S.F. Footprint analysis of replicating murine leukemia virus reverse transcriptase. Science 267 (1995) 96-99
55. Tong W., Lu C.D., Sharma S.K., Matsuura S., So A.G., and Scott W.A. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36 (1997) 5749-5757
56. Rothwell P.J., Berger S., Kensch O., Felekyan S., Antonik M., Wohrl B.M., Restle T., Goody R.S., and Seidel C.A. Multiparameter single-molecule fluorescence spectroscopy reveals heterogeneity of HIV-1 reverse transcriptase: primer/template complexes. Proc. Natl. Acad. Sci. USA 100 (2003) 1655-1660
57. Tachedjian G., Orlova M., Sarafianos S.G., Arnold E., and Goff S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 98 (2001) 7188-7193
58. Basavapathruni A., Bailey C.M., and Anderson K.S. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279 (2004) 6221-6224
59. Sluis-Cremer N., and Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 269 (2002) 5103-5111
60. Tachedjian G., Aronson H.E., De los Santos M., Seehra J., McCoy J.M., and Goff S.P. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J. Mol. Biol. 326 (2003) 381-396
61. Tachedjian G., and Goff S.P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Investig. Drugs 4 (2003) 966-973
62. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., and Steitz T.A. Crystal structure at 3.5. A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
63. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A., and Arnold F. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243 (1994) 369-387
64. Mizushina Y., Yoshida S., Matsukage A., and Sakaguchi K. The inhibitory action of fatty acids on DNA polymerase beta. Biochim. Biophys. Acta 1336 (1997) 509-521
65. Mizushina Y., Ohkubo T., Date T., Yamaguchi T., Saneyoshi M., Sugawara F., and Sakaguchi K. Mode analysis of a fatty acid molecule binding to the N-terminal 8-kDa domain of DNA polymerase beta A 1:1 complex and binding surface. J. Biol. Chem. 274 (1999) 25599-25607
66. Delagoutte E., and Von Hippel P.H. Function and assembly of the bacteriophage T4 DNA replication complex: interactions of the T4 polymerase with various model DNA constructs. J. Biol. Chem. 278 (2003) 25435-25447
67. Heidenreich O., Kruhoffer M., Grosse F., and Eckstein F. Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3′-azidothymidine triphosphate. Eur. J. Biochem. 192 (1990) 621-625